1.5 CONCLUSION
Our adjusted QTc-prolongation risk score, with a cutoff of 5 points, predicted a QTc interval ≥ 450 ms for males, ≥ 470 ms for females, or an increase from baseline ECG by ≥ 30 ms with a sensitivity of 68%, a specificity of 66%, a PPV of 45% and an NPV of 83%. These results will allow us to integrate the risk score into the EHR as a guidance tool to predict QTc-prolongation.
AUTHOR CONTRIBUTIONS: All authors have made substantial contributions to the design, analysis, and interpretation of this work. All authors have contributed to the drafting, reviewing, and approval of this work and agree to be accountable for all aspects of this work’s accuracy and integrity.
ACKNOWLEDGEMENTS: The authors thank Elie Mouhayar, MD for his support and clinical input regarding the risk score; Robert McDaniel, PharmD, BCPS and Hannah Aune, PharmD, BCPS for their feedback and suggestions; Francis Simms, CPhT and Gilbert Castro, CPhT for helping with the score build in the EHR.